leisure time -WSS

leisure time

author：comprehensive 2025-09-28 12:10:15 - browse：71

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： RaDonda Vaught links Vanderbilt hospital issues to patient death

Wikipedia

hotspot

WSS

Biden administration opens offers in Medicare drug price negotiations

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Cybersecurity threat forces Lurie Children's to take systems offline

Why depression after traumatic brain injury is distinct

Amid AI frenzy, a top HHS official's quest to create safeguards

explore

leisure time

explore

Trump demands the U.S. pay no more for drugs than other countries … again

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Affirmative action in medical school literally saved lives

As AI in medicine takes off, can 'human in the loop' prevent harm?

Tori Bowie and the unacceptable rates of Black maternal death

Congressmen charge Covid hearing ‘could have been an email’

Dobbs anniversary: the lost opportunity of abortion as health care

RaDonda Vaught links Vanderbilt hospital issues to patient death

Psychedelics group wrestles with new pharma identity

FDA drug safety: Singulair case shows systemic surveillance flaws

knowledge

Novo Nordisk to expand supply of Wegovy for U.S. patients

How many hemophilia patients actually want gene therapy?

How to save health care price transparency rules

General Catalyst, Summa Health deal will turn on physician buy

How many hemophilia patients actually want gene therapy?

FDA advisers back CAR

Wikipedia

knowledge

hotspot

explore